Cargando…

New Routes in GPCR/β-Arrestin-Driven Signaling in Cancer Progression and Metastasis

Tumor cells acquire invasive and metastatic behavior by sensing changes in the localization and activation of signaling pathways, which in turn determine changes in actin cytoskeleton. The core-scaffold machinery associated to β-arrestin (β-arr) is a key mechanism of G-protein coupled receptors (GPC...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagnato, Anna, Rosanò, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390811/
https://www.ncbi.nlm.nih.gov/pubmed/30837880
http://dx.doi.org/10.3389/fphar.2019.00114
_version_ 1783398210838986752
author Bagnato, Anna
Rosanò, Laura
author_facet Bagnato, Anna
Rosanò, Laura
author_sort Bagnato, Anna
collection PubMed
description Tumor cells acquire invasive and metastatic behavior by sensing changes in the localization and activation of signaling pathways, which in turn determine changes in actin cytoskeleton. The core-scaffold machinery associated to β-arrestin (β-arr) is a key mechanism of G-protein coupled receptors (GPCR) to achieve spatiotemporal specificity of different signaling complexes driving cancer progression. Within different cellular contexts, the scaffold proteins β-arr1 or β-arr2 may now be considered organizers of protein interaction networks involved in tumor development and metastatic dissemination. Studies have uncovered the importance of the β-arr engagement with a growing number of receptors, signaling molecules, cytoskeleton regulators, epigenetic modifiers, and transcription factors in GPCR-driven tumor promoting pathways. In many of these molecular complexes, β-arrs might provide a physical link to active dynamic cytoskeleton, permitting cancer cells to adapt and modify the tumor microenvironment to promote the metastatic spread. Given the complexity and the multidirectional β-arr-driven signaling in cancer cells, therapeutic targeting of specific GPCR/β-arr molecular mechanisms is an important avenue to explore when considering future new therapeutic options. The focus of this review is to integrate the most recent developments and exciting findings of how highly connected components of β-arr-guided molecular connections to other pathways allow precise control over multiple signaling pathways in tumor progression, revealing ways of therapeutically targeting the convergent signals in patients.
format Online
Article
Text
id pubmed-6390811
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63908112019-03-05 New Routes in GPCR/β-Arrestin-Driven Signaling in Cancer Progression and Metastasis Bagnato, Anna Rosanò, Laura Front Pharmacol Pharmacology Tumor cells acquire invasive and metastatic behavior by sensing changes in the localization and activation of signaling pathways, which in turn determine changes in actin cytoskeleton. The core-scaffold machinery associated to β-arrestin (β-arr) is a key mechanism of G-protein coupled receptors (GPCR) to achieve spatiotemporal specificity of different signaling complexes driving cancer progression. Within different cellular contexts, the scaffold proteins β-arr1 or β-arr2 may now be considered organizers of protein interaction networks involved in tumor development and metastatic dissemination. Studies have uncovered the importance of the β-arr engagement with a growing number of receptors, signaling molecules, cytoskeleton regulators, epigenetic modifiers, and transcription factors in GPCR-driven tumor promoting pathways. In many of these molecular complexes, β-arrs might provide a physical link to active dynamic cytoskeleton, permitting cancer cells to adapt and modify the tumor microenvironment to promote the metastatic spread. Given the complexity and the multidirectional β-arr-driven signaling in cancer cells, therapeutic targeting of specific GPCR/β-arr molecular mechanisms is an important avenue to explore when considering future new therapeutic options. The focus of this review is to integrate the most recent developments and exciting findings of how highly connected components of β-arr-guided molecular connections to other pathways allow precise control over multiple signaling pathways in tumor progression, revealing ways of therapeutically targeting the convergent signals in patients. Frontiers Media S.A. 2019-02-19 /pmc/articles/PMC6390811/ /pubmed/30837880 http://dx.doi.org/10.3389/fphar.2019.00114 Text en Copyright © 2019 Bagnato and Rosanò. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Bagnato, Anna
Rosanò, Laura
New Routes in GPCR/β-Arrestin-Driven Signaling in Cancer Progression and Metastasis
title New Routes in GPCR/β-Arrestin-Driven Signaling in Cancer Progression and Metastasis
title_full New Routes in GPCR/β-Arrestin-Driven Signaling in Cancer Progression and Metastasis
title_fullStr New Routes in GPCR/β-Arrestin-Driven Signaling in Cancer Progression and Metastasis
title_full_unstemmed New Routes in GPCR/β-Arrestin-Driven Signaling in Cancer Progression and Metastasis
title_short New Routes in GPCR/β-Arrestin-Driven Signaling in Cancer Progression and Metastasis
title_sort new routes in gpcr/β-arrestin-driven signaling in cancer progression and metastasis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390811/
https://www.ncbi.nlm.nih.gov/pubmed/30837880
http://dx.doi.org/10.3389/fphar.2019.00114
work_keys_str_mv AT bagnatoanna newroutesingpcrbarrestindrivensignalingincancerprogressionandmetastasis
AT rosanolaura newroutesingpcrbarrestindrivensignalingincancerprogressionandmetastasis